Omega Pharma Sells Aresus Stake To Focus On OTC Drug Market

Continuing with its aim of strengthening its core over-the-counter (OTC) medicines business, Belgium-based Omega Pharma has agreed to sell its remaining 24.0% stake in medical devices company Arseus to private equity group Waterland, making Waterland Arseus's new main shareholder. BMI believes the company's decision to focus on the OTC market is a wise one. In 2008, the OTC market in the 28 countries in BMI's Europe coverage was worth US$47.4bn and by 2013 we forecast this figure to increase to US$54.4bn.

To read the full article, please sign in or take a free trial.